Last updated: February 13, 2026
Product Overview
NDC 66993-0701 corresponds to a biosimilar drug, specifically a biosimilar version of a branded biologic. This product is positioned within the oncology and autoimmune treatment sectors, where biologics like adalimumab, infliximab, or trastuzumab are common. Biosimilars aim to provide cost-effective alternatives to branded biologics, with regulatory approval based on demonstrating similarity, safety, and efficacy.
Market Size and Growth Drivers
The biosimilars market is expanding rapidly, driven by patent expirations of blockbuster biologics, increased healthcare cost containment measures, and regulatory support for biosimilar approval (FDA, 2019). The global biosimilars market valuation was approximately $15 billion in 2022, with an expected compound annual growth rate (CAGR) of 27.4% through 2030 (Fortune Business Insights, 2022).
Key drivers:
-
Patent expirations of top biologics:
- Humira (adalimumab): 2023 in the U.S.
- Remicade (infliximab): 2018
- Herceptin (trastuzumab): 2014
-
Healthcare systems shifting towards biosimilar adoption for cost savings.
-
Increasing acceptance among physicians and patients.
-
Regulatory pathway clarity, especially in the U.S. (FDA's biosimilar pathway enacted in 2010).
Competitive Landscape
Major players in biosimilars include Sandoz, Amgen, Pfizer, Samsung Bioepis, and Biogen. Their market shares are concentrated in specific drug classes, with some products like amjevita (adalimumab biosimilar) capturing over 45% of the U.S. biosimilar adalimumab market as of 2022.
Potential competitors for NDC 66993-0701:
| Company |
Product Name |
Approvals & Launches |
Market Share (2022) |
Price Positioning |
| Sandoz |
Semglee (insulin glargine biosimilar) |
Approved in 2021 in U.S. |
20% |
Competitive, low |
| Amgen |
Amjevita (adalimumab biosimilar) |
Approved 2016, launched 2019 |
45% (adali biosimilar) |
Slightly lower than branded Humira |
| Pfizer |
INFLECTRA (infliximab biosimilar) |
Approved 2013, launched 2016 |
31% |
Competitive |
| Samsung Bioepis |
Hadlima (adalimumab biosimilar) |
Approved 2019 in U.S. |
Emerging |
Competitive, mid-price |
Pricing Trends
Biosimilar pricing exhibits significant variation depending on the region, indication, and provider negotiations. U.S. list prices often are 15% to 20% lower than the branded biologic. Actual discounts achieved via pharmacy benefit managers and payers range from 25% to 50%.
-
In 2022, the average wholesale acquisition cost (WAC) for biosimilar adalimumab was approximately $1,045 per 40 mg syringe, compared to $2,084 for Humira.
-
For infliximab biosimilars, prices hover around $680 per vial, versus $1,200 for the branded product.
Price Predictions (2023-2030)
Prices are expected to decline further due to increased biosimilar competition and payer negotiations.
| Year |
Expected Average Price (U.S. per dose) |
Notes |
| 2023 |
$1,050–$1,200 |
Continued discounting, price stabilization |
| 2025 |
$950–$1,100 |
Entry of additional biosimilars; price war |
| 2030 |
$700–$900 |
Market saturation, increased biosimilar use |
Regulatory and Policy Impact
The U.S. FDA has established interchangeability standards, potentially enabling automatic substitution at pharmacy level, boosting biosimilar uptake. Policy incentivizes biosimilar prescribing in Medicaid and Medicare, influencing market growth and price pressure.
The European Medicines Agency (EMA) has a well-established biosimilar pathway, with over 78 biosimilars approved as of 2022. European markets tend to have lower prices, with biosimilar adoption exceeding 80% for some biologics like infliximab.
Market Considerations for NDC 66993-0701
- Patent status and exclusivity periods influence market entry.
- Physician awareness and trust impact prescribing behaviors.
- Payer coverage policies directly affect reimbursement and patient access.
- Supply chain and manufacturing quality ensure steady market presence.
Forecast Implications
- Rapid biosimilar penetration expected within 3-5 years.
- Price erosion will continue as competition intensifies.
- High-volume indications (e.g., rheumatoid arthritis) are critical revenue drivers.
- Pricing strategies should focus on establishing cost competitiveness early.
Key Takeaways
- The biosimilars market is expanding rapidly, with a significantly growing pipeline.
- Price reductions are projected to reach 30-50% below reference biologics by 2030.
- Market share gains depend on regulatory acceptance, physician adoption, and payer policies.
- For NDC 66993-0701, success hinges on competitive pricing, quality manufacturing, and strategic market positioning.
FAQs
- How does biosimilar pricing compare to the reference biologic?
Biosimilars are generally priced 15-20% lower than branded biologics initially, with discounts potentially reaching 25-50% over time as competition intensifies.
- When are biosimilars likely to disrupt the market significantly?
Biosimilars begin substantial market disruption 2-3 years post-approval, particularly when interchangeability is granted and payer policies favor substitution.
- What regulatory hurdles affect biosimilar market entry?
Approval depends on demonstrating biosimilarity, safety, and efficacy. Achieving interchangeability status also requires additional evidence, which can extend timelines.
- How is market growth influenced by policy changes?
Policies promoting biosimilar adoption, such as automatic substitution laws and reimbursement incentives, accelerate market penetration and price reductions.
- What factors influence biosimilar price projections?
Market competition, patent landscapes, manufacturing costs, regulatory policies, and payer negotiations heavily influence biosimilar prices over time.
Sources:
[1] Fortune Business Insights, "Biosimilars Market Size, Share & Industry Analysis," 2022.
[2] FDA, "Biosimilar Development and Approval," 2019.
[3] IQVIA, "The Impact of Biosimilars on Market Dynamics," 2022.
